KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.

Ken Mautner, Michael Gottschalk, Scott D Boden, Alison Akard, Won C Bae, Lora Black, Blake Boggess, Paramita Chatterjee, Christine B Chung, Kirk A Easley, Greg Gibson, Josh Hackel, Katie Jensen, Linda Kippner, Chad Kurtenbach, Joanne Kurtzberg, R Amadeus Mason, Benjamin Noonan, Krishnendu Roy, Verle Valentine, Carolyn Yeago, Hicham Drissi

Nat Med 29(12) 3120-3126

PMID37919438
PMCIDPMC10719084
DOI10.1038/s41591-023-02632-w
发表日期2023-11-03
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Various types of cellular injection have become a popular and costly treatment option for patients with knee osteoarthritis despite a paucity of literature establishing relative efficacy to each other or corticosteroid injections. Here we aimed to identify the safety and efficacy of cell injections from autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic human umbilical cord tissue-derived mesenchymal stromal cells, in comparison to corticosteroid injection (CSI). The study was a phase 2/3, four-arm parallel, multicenter, single-blind, randomized, controlled clinical trial with 480 patients with a diagnosis of knee osteoarthritis (Kellgren-Lawrence II-IV). Participants were randomized to the three different arms with a 3:1 distribution. Arm 1: autologous bone marrow aspirate concentrate (n = 120), CSI (n = 40); arm 2: umbilical cord tissue-derived mesenchymal stromal cells (n = 120), CSI (n = 40); arm 3: stromal vascular fraction (n = 120), CSI (n = 40). The co-primary endpoints were the visual analog scale pain score and Knee injury and Osteoarthritis Outcome Score pain score at 12 months versus baseline. Analyses of our primary endpoints, with 440 patients, revealed that at 1 year post injection, none of the three orthobiologic injections was superior to another, or to the CSI control. In addition, none of the four groups showed a significant change in magnetic resonance imaging osteoarthritis score compared to baseline. No procedure-related serious adverse events were reported during the study period. In summary, this study shows that at 1 year post injection, there was no superior orthobiologic as compared to CSI for knee osteoarthritis. ClinicalTrials.gov Identifier: NCT03818737.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。